恒瑞医药注射用SHR-A1904纳入突破性治疗品种名单

Core Viewpoint - Heng Rui Medicine announced that its injectable SHR-A1904 has been included in the list of breakthrough therapies by the National Medical Products Administration, targeting CLDN18.2 positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma patients who have previously received at least first-line systemic treatment [1] Group 1 - The injectable SHR-A1904 is developed by Heng Rui Medicine and its subsidiary Shanghai Heng Rui Medicine Co., Ltd [1] - The indication for SHR-A1904 is specifically for patients with CLDN18.2 positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma [1] - The inclusion in the breakthrough therapy list signifies a potential acceleration in the development and review process for this treatment [1]